Shares of Beam Therapeutics BEAM had been up 22.3% on Monday after the corporate outlined strategic priorities and a few anticipated milestones associated to its gene remedy pipeline candidates for 2026.
Beam Therapeutics’ genetic illness pipeline contains BEAM-301 and BEAM-302, that are being developed for the therapy of glycogen storage illness sort 1a (GSD1a) and alpha-1 antitrypsin deficiency (“AATD”), respectively, in separate research.
BEAM’s Current Updates on BEAM-302 & BEAM-301
Beam Therapeutics’ lead genetic illness pipeline candidate, BEAM-302, is being evaluated in an open-label section I/II examine for treating AATD, addressing the underlying pathophysiology of each liver and lung illness. Greater than 25 AATD sufferers with lung and/or liver illness have been handled with BEAM-302 within the dose-exploration parts of the examine up to now.
AATD is an inherited genetic dysfunction that may trigger early onset of emphysema and liver illness. At the moment, there are not any authorised healing therapies for the given indication.
Per the newest replace, BEAM has reached alignment with the FDA on a possible accelerated approval pathway for BEAM-302 primarily based on AAT biomarker knowledge evaluated over 12 months. To help a future BLA submitting for BEAM-302, the corporate plans to enroll round 50 extra sufferers on the optimum biologic dose of BEAM-302 in an growth of the continuing section I/II examine.
Up to date knowledge from the section I/II examine and subsequent steps for pivotal improvement of BEAM-302 are anticipated to be introduced by the top of the primary quarter of 2026.
The FDA has additionally accepted BEAM-302 into its Chemistry, Manufacturing, and Controls Improvement and Readiness Pilot (CDRP) program, which helps quicker chemistry, manufacturing, and controls improvement for merchandise with accelerated medical timelines.
BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base modifying reagents designed to appropriate the disease-causing PiZ mutation.
In the meantime, BEAM-301 is presently being evaluated in an open-label section I/II dose-exploration examine for treating sufferers with GSDIa. Preliminary knowledge from the examine is predicted later in 2026.
Beam Therapeutics additionally plans to unveil its subsequent medical program for the liver-targeted genetic illness franchise within the first half of 2026.
BEAM’s Worth Efficiency
A number of traders and Wall Avenue analysts expressed optimism round Beam Therapeutics’ replace associated to BEAM-302 as the corporate reached alignment with the FDA on a possible accelerated approval pathway. Traders additionally appeared impressed with the corporate’s different pipeline objectives, which resulted within the inventory value rising on Jan. 12.
Up to now six months, shares of Beam Therapeutics have rallied 59.1% in contrast with the trade’s improve of 21%.
Picture Supply: Zacks Funding Analysis
BEAM’s Current Updates With Risto-Cel
Beam Therapeutics is creating its hemoglobinopathy candidate, ristoglogene autogetemcel (risto-cel, previously often called BEAM-101), an ex vivo remedy being evaluated within the section I/II BEACON examine for treating sickle cell illness (“SCD”).
Final month, BEAM reported up to date knowledge from this examine on the 2025 ASH annual assembly, which continued to point out proof of risto-cel’s differentiated therapy profile in SCD sufferers.
Moreover, Beam Therapeutics has additionally accomplished discussions with the FDA on the deliberate biologics licensing utility (BLA) package deal for risto-cel, which is predicted to comply with the regulatory precedent set by beforehand authorised SCD gene therapies. The corporate plans to submit a BLA for risto-cel as early as year-end 2026.
The FDA has additionally accepted risto-cel in its CDRP program.
Beam Therapeutics not too long ago initiated dosing in a section I wholesome volunteer examine evaluating BEAM-103, an experimental anti-CD117 monoclonal antibody for the therapy of SCD.
Beam Therapeutics ended 2025 with roughly $1.25 billion in money, money equivalents and marketable securities, offering important monetary flexibility to fund ongoing medical applications. Administration expects this money stability to fund the corporate’s anticipated working bills and capital expenditure necessities into 2029 whereas additionally aiding the launch of risto-cel in SCD and execution of the BEAM-302 pivotal improvement plan in AATD.
BEAM’s Zacks Rank & Shares to Think about
Beam Therapeutics presently carries a Zacks Rank #4 (Promote).
Some better-ranked shares within the biotech sector are Keros Therapeutics KROS, Precise Sciences EXAS and Immunocore IMCR, every carrying a Zacks Rank #1 (Sturdy Purchase). You’ll be able to see the whole listing of right now’s Zacks #1 Rank shares right here.
Up to now 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.65 to $3.47. Up to now six months, shares of KROS have risen 29.6%.
Keros Therapeutics’ earnings beat estimates in three of the trailing 4 quarters, whereas lacking the mark on one event. On common, the corporate delivered a shock of 9,098.63%.
Up to now 60 days, estimates for Precise Sciences’ 2026 earnings per share have moved up from $1.35 to $1.40. EXAS inventory has surged 88.2% previously six months.
Precise Sciences’ earnings beat estimates in every of the trailing 4 quarters, with the common shock being 352.28%.
Up to now 60 days, 2026 loss per share estimates for Immunocore have narrowed from $1.18 to 90 cents. Up to now six months, shares of IMCR have misplaced 7.5%.
Immunocore’s earnings beat estimates in three of the trailing 4 quarters, whereas lacking the mark on one event. On common, the corporate delivered a shock of 53.96%.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our crew of consultants has simply launched the 5 shares with the best chance of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This prime choose is a little-known satellite-based communications agency. House is projected to turn into a trillion greenback trade, and this firm’s buyer base is rising quick. Analysts have forecasted a significant income breakout in 2025. In fact, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Hims & Hers Well being, which shot up +209%.
Free: See Our High Inventory And 4 Runners Up
Beam Therapeutics Inc. (BEAM) : Free Inventory Evaluation Report
Precise Sciences Company (EXAS) : Free Inventory Evaluation Report
Keros Therapeutics, Inc. (KROS) : Free Inventory Evaluation Report
Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
